# US 2008/0306108 A1 · Substituted Pyridoxines As Anti-Platelet Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306108 A1
- Document ID: US20080306108A1
- Status: Published application
- Kind: A1
- Application number: 12/134,622
- Filed: 2008-06-06
- Published: 2008-12-11
- Earliest claimed: 2004-10-28
- Assignees: Medicure International Inc.
- Inventors: Wasimul Haque; James Diakur; Vinh Pham; Wenlian Zhang
- Web page: https://patentgrep.com/patent/US20080306108A1

## CPC

- C07D 213/66: having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/65: attached in position 3 or 5
- C07D 213/79: Acids; Esters
- C07D 491/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds with antiplatelet aggregation characteristics for the treatment of cardiovascular and cardiovascular related disease, are described. The methods are directed to administering pharmaceutical compositions comprising a pyridoxine analogue.

## Claims

### Claim 1

A compound of the formula:
wherein
R1 is OH, O-alkyl, or O-alkyl-aryl-R4, where R4 is H, —CN, amidine, alkyl, or cycloalkyl;
R2 is alkyl; —(CH2)n′OH where n′ is an integer from 1 to 8; —(CH2)nCOOH where n is an integer from 0 to 8; —(CH2)nCOO(CH2)nCH3 where n is as defined above; (CH2)n-aryl-R5 where n is as defined above, and R5 is —CN or amidine; (CH2)n-aryl-aryl-R5, where n and R5 are as defined above; (CH2)n—NH-aryl-R5, where n and R5 are as defined above; (CH2)n—NH—CO-aryl-R4 where n and R4 are as defined above; (CH2)n—NH-aryl-aryl-R5 where n and R5 are as defined above; and (CH2)n—NH—CO-aryl-aryl-R6 where n is as defined above and R6 is —CN, —NO2, NH2, or amidine;
R3 is —(CH2)n′OH where n′ is as defined above; (CH2)n—NH-aryl-R5, where n and R5 are as defined above; (CH2)n—NH—CO-aryl-R6 where n and R4 are as defined above; (CH2)n—NH-aryl-aryl-R5 where n and R5 are as defined above; and (CH2)n—NH—CO-aryl-aryl-R6 where n and R6 are as defined above; and
R1 and R2 when taken together can form a compound of the formula
wherein R3 is as defined above, with the proviso that R3 cannot be CH2—NH-Phenyl-R5 or CH2—NH-Phenyl-Phenyl-R5; and
wherein only one of R4, R5, and R6 can be amidine; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The compound of claim 1, wherein an alkyl of 1-8 carbon atoms is unsubstituted or substituted with one or more of fluorine, chlorine, alkoxy groups of 1 to 8 carbon atoms, or amido groups having from 1 to 8 carbon atoms.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the alkoxy group is methoxy or ethoxy.

### Claim 5 (depends on 3)

The compound of claim 3, wherein the amido group is acetamido.

### Claim 6 (depends on 1)

The compound of claim 1, wherein an aryl group is a phenyl group or a naphthyl group.

### Claim 7 (depends on 1)

The compound of claim 1, wherein an aryl group is substituted with one or more of fluorine, chlorine, bromine, alkyl groups having 1 to 8 carbon atoms, alkoxy groups having 1 to 8 carbon atoms, alkoxyalkyl groups having 1 to 8 carbon atoms and one or more oxygen atoms, or amido groups having 1 to 8 carbon atoms.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the alkyl group is methyl or ethyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein the alkoxy group is methoxy or ethoxy.

### Claim 10 (depends on 7)

The compound of claim 7, wherein the amido group is acetamido.

### Claim 11

(canceled)

### Claim 12 (depends on 11)

The compound of claim 11, wherein the functional group is a hydroxy group, carboxy group, or acetoxy group.

### Claim 13

A compound of the formula
wherein
R1 is OH, OCH3, or OCH2-(4-tert-butylphenyl);
R2 is CH2OH, CH2OCH3, CH2OBn, CH3,
or COOR11 where R11 is H or alkyl;
W is (CH2), where n′=1, 2 or 3, or C═O;
X is (CH2)n where n=0, 1, 2, or 3, C═O, or CHCH2CO2H;
Y is C—H, C—F, C—OCH3, C—OCF3, C—CF3, or N;
R9 is
Where R12 is H, OH or O-alkyl;
R10 is H, CH2—Ar—R9 where R9 is defined as above;
R1 and R2 taken together can form a compound of the formula IV
wherein W, X, Y, R3 and R4 are as described above; and
only one of R3 and R4 can be
R12 is as described above; or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The compound of claim 13, wherein the compound is 4-Carbamimidoyl-N-(5-hydroxyl-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-benzamide.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the compound is 4′-Carbamimidoyl-biphenyl-4-carboxylic (5-hydroxyl-4-hydroxymethyl-6-methyl-pyridin-3-ylmethyl)-amide.

### Claim 16 (depends on 13)

The compound of claim 13, wherein the compound is 4′-[(5-Hydroxy-4,6-dimethyl-pyridin-3-ylmethyl)-amino]-biphenyl-4-carboxamidine.

### Claim 17 (depends on 13)

The compound of claim 13, wherein the compound is 4-(N-(4-Carbamimidoyl-benzyl)-N-((5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl)methyl)amino)benzamidine.

### Claim 18 (depends on 1)

A method of treating cardiovascular, cerebro-vascular, or related diseases and symptoms in a mammal comprising administering a therapeutically effective amount of a compound according to claim 1.

### Claim 19

(canceled)

### Claim 20 (depends on 13)

A method of treating cardiovascular, cerebro-vascular, or related diseases and symptoms in a mammal comprising administering a therapeutically effective amount of a compound according to claim 13.

### Claim at position 21

21-26. (canceled)

### Claim 27 (depends on 1)

A method of treating a mammal post-surgically comprising administering a therapeutically effective amount of a compound according to claim 1 following a surgical procedure.

### Claim at position 23

28-33. (canceled)

### Claim 34 (depends on 13)

A method of treating a mammal post-surgically comprising administering a therapeutically effective amount of a compound according to claim 13 following a surgical procedure.

### Claim at position 25

35-48. (canceled)
